reports
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
Dynamic Top Pick List Update April 2026: Adding Fagron
The tariff war between US and China has eased, but with the Iran conflict and an erratic Trump, uncertainty will continues unabated. Energy prices have gone ballistic, with gas prices doubling in Europe and has hit the cyclical stocks hard. KBC macro-econimists have hiked the inflation expectation for 2026 from 1.9% to 3.3%. While the macro-economic impact has been limited so far, a prolonged uncertain situation will result in economic damage. We continue our defensive stance in our Benelux Dyna...
FAGR FAGRON SA
WKL WOLTERS KLUWER NV
EVS EVS BROADCAST EQUIPMENT SA
UCB UCB S.A.
DIE D'IETEREN SA
SOF SOFINA SA
IBAB ION BEAM APPLICATIONS SA
ROYAL VOPAK NV
CSM CORBION NV
ABI ANHEUSER-BUSCH INBEV SA/NV
ARGX ARGEN-X SE
WDP WAREHOUSES DE PAUW SCA
AZE AZELIS GROUP NV
DEME DEME GROUP NV
SHUR SHURGARD SELF STORAGE LIMITED
Corbion published agenda for AGM
Corbion published agenda for AGM Corbion has published its agenda for the upcoming Annual General Meeting of Shareholders (AGM) to be held on 13 May 2026. The full AGM agenda together with explanatory notes is available on Corbion's under Investor relations --> Shareholder information --> Shareholder meetings. Attachment
CMB.TECH announces final year results
CMB.TECH announces final year results CMB.TECH ANNOUNCES FINAL YEAR RESULTS ANTWERP, Belgium, 31 March 2026 – CMB.TECH NV (“CMBT”, “CMB.TECH” of “the company” (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) reported its final financial results today for the full year ended 31 December 2025. HIGHLIGHTS 2025 Financial highlights: Profit of USD 89.1 million in Q4 2025 bringing full year profit to USD 139.1 million No major changes compared to the preliminary figures published on 26/2/26Total contract backlog increased to USD 3.05 billion Fleet highlights: CMB.TECH f...
- Jean-François Granjon
- Louis Boujard
- CFA
EVT EVOTEC SE
PHA PHARMAGEST INTERACTIVE SA
ALDEL DELFINGEN INDUSTRY SA
OERL OC OERLIKON CORPORATION AG
VRAP VRANKEN-POMMERY MONOPOLE SA
NOEJ NORMA GROUP SE
POS PORR AG
ADN1 ADESSO AG
ALBFR SIDETRADE SA
SMHN SUESS MICROTEC AG
CSM CORBION NV
WPL WIRTUALNA POLSKA HOLDING SA
DMP DERMAPHARM HOLDING SE
ATRY ATRYS HEALTH
S30 SOLUTIONS 30 SE
KTA KNAUS TABBERT
LHYFE LHYFE S.A.
CO CASINO GUICHARD-PERRACHON
- Jean-François Granjon
- Louis Boujard
- CFA
EVT EVOTEC SE
PHA PHARMAGEST INTERACTIVE SA
ALDEL DELFINGEN INDUSTRY SA
OERL OC OERLIKON CORPORATION AG
VRAP VRANKEN-POMMERY MONOPOLE SA
VETO VETOQUINOL SA
NOEJ NORMA GROUP SE
POS PORR AG
ADN1 ADESSO AG
ALBFR SIDETRADE SA
SMHN SUESS MICROTEC AG
CSM CORBION NV
WPL WIRTUALNA POLSKA HOLDING SA
DMP DERMAPHARM HOLDING SE
ATRY ATRYS HEALTH
S30 SOLUTIONS 30 SE
KTA KNAUS TABBERT
LHYFE LHYFE S.A.
CO CASINO GUICHARD-PERRACHON
- Jacob Mekhael
Galapagos Signs agreement with Gilead on T-cell Engager in autoimmune ...
Galapagos announced that, following Gilead entering into a definitive agreement to acquire Ouro Medicines for $1,675m in cash consideration, and up to $500m in contingent milestone payments, Galapagos and Gilead have now entered into a binding agreement to collaborate on advancing gamgertamig (BCMAxCD3 T cell engager) in autoimmune diseases. This agreement comes after the companies announced their advanced discussions on the collaboration last week. Economically, Galapagos is effectively co-fina...
- Guy Sips
- Jacob Mekhael
- Mathijs Geerts Danau
- Wim Lewi
- Robert Jan Vos
Progress on share buyback programme
Progress on share buyback programme Progress on share buyback programme ING announced today that, as part of our €1.1 billion share buyback programme announced on 30 October 2025, in total 2,262,425 shares were repurchased during the week of 23 March up to and including 27 March 2026. The shares were repurchased at an average price of €21.93 for a total amount of €49,619,703.42. For detailed information on the daily repurchased shares, individual share purchase transactions and weekly reports, see the updates on the on our website. In line with the purpose of the programme to reduce the...
Galapagos en Gilead gaan definitieve overeenkomst aan over samenwerkin...
Galapagos en Gilead gaan definitieve overeenkomst aan over samenwerking om een first-in-class T-cel-engagerprogramma voor auto-immuunziekten verder te ontwikkelen De nieuwe samenwerkingsstructuur levert aanzienlijk verbeterde financiële voorwaarden en flexibiliteit voor Galapagos op Na deze transactie blijft de Vennootschap over het grootste deel van haar liquide middelen beschikken voor bijkomende strategische transacties en andere prioriteiten van kapitaalallocatie Kans om met gamgertamig een potentieel first-in-class & best-in-class T-cell-engager in auto-immuunziekten te ontwikkelen ...
Galapagos and Gilead Enter into Binding Agreement to Collaborate on Ad...
Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos Following this transaction, the Company will continue to have a majority of its cash remaining for additional strategic transactions and other capital allocation priorities Opportunity to develop a potential first-in-class & best-in-class T cell engager in autoimmune diseases with gamgertamig Management to host conference call today, March 31, 20...
- Reg Watson
- CFA
Corbion/Goldilocks scenario extends/HOLD
Since our 12-month target price upgrade to €18.60 and change in recommendation from Sell to HOLD on 17 November 2025, Corbion has delivered its Capital Markets Day and full year results. Corbion confirmed at its 2025 results that the company had taken advantage of the low sugar price to hedge all its exposure for 2026 and 75% for 2027. This extends the Goldilocks scenario of lower costs and higher revenues from 2026 into 2027 and supports approximately half of the company's guided adj. EBITDA ma...
Galapagos kondigt de voordracht aan van Gino Santini tot lid van de Ra...
Galapagos kondigt de voordracht aan van Gino Santini tot lid van de Raad van Bestuur De Raad van Bestuur is voornemens de heer Santini te benoemen tot Voorzitter, als opvolger van Jérôme Contamine, onder voorbehoud van zijn benoeming door aandeelhouders De heer Santini zal uitgebreide ervaring op het gebied van corporate governance, bedrijfsontwikkeling en leiderschap in de sector toevoegen aan de Raad van Bestuur Mechelen, België; 26 maart, 2026, 21:02 CET — Galapagos NV (Euronext & NASDAQ: GLPG), heeft vandaag bekendgemaakt dat Gino Santini is voorgedragen als Niet-Uitvoerend Onafhankel...
Galapagos Announces Nomination of Gino Santini to its Board of Directo...
Galapagos Announces Nomination of Gino Santini to its Board of Directors Subject to his election by shareholders, the Board intends to appoint Mr. Santini as Chair, succeeding Jérôme Contamine Mr. Santini will bring extensive corporate governance, business development and industry leadership experience to the Board Mechelen, Belgium; March 26, 2026, 21:02 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced the proposed appointment of Gino Santini as a Non-Executive Independent Director, with the intention to appoint him as Chair of its Board of Directors, subject to shareholder...
Galapagos Publishes 2025 Annual Report and Announces Annual and Extrao...
Galapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders’ Meetings Mechelen, Belgium; March 26, 2026, 21:01 CET; regulated information — Galapagos NV (Euronext & NASDAQ: GLPG) today published its annual report for the financial year 2025 and announced that its Annual Shareholders’ Meeting (AGM) and an Extraordinary Shareholders' Meeting (EGM) will be held sequentially on Tuesday, April 28, 2026 at 14:00 CET and 15:00 CET at Schaliënhoevedreef 20T, 2800 Mechelen, Belgium. The annual report for the financial year 2025, including a review of figures and perfo...
Galapagos publiceert 2025 jaarverslag en kondigt de Gewone (jaarlijkse...
Galapagos publiceert 2025 jaarverslag en kondigt de Gewone (jaarlijkse) en Buitengewone Algemene Vergaderingen aan Mechelen, België; 26 maart, 2026, 21:01 CET; gereglementeerde informatie — Galapagos NV (Euronext & NASDAQ: GLPG) heeft vandaag haar jaarverslag over het boekjaar 2025 gepubliceerd en aangekondigd dat haar Gewone (jaarlijkse) Algemene Vergadering (GAV) en een Buitengewone Algemene Vergadering (BAV) achtereenvolgens zullen plaatsvinden op dinsdag 28 april 2026 om 14.00 uur en 15.00 uur te Schaliënhoevedreef 20T, 2800 Mechelen, België. Het jaarverslag over het boekjaar 2025, inc...
- ING Helpdesk
Benelux Morning Notes
Ageas: FY25 results of CTIH. ASR: Management & Supervisory Board changes. MICC: Preview 1Q26. Ontex: 1Q26 preview - markets remain challenging. Randstad: Preliminary preview 1Q26F results due 22 April. Tessenderlo: 2H25 miss, soft 2026F guidance. Unicredit: Injecting capital into its Belgian Bank
- Elias New
- Nicolas David
- Sinan Doganli
- Elias New
- Nicolas David
- Sinan Doganli
- Jacob Mekhael
Galapagos Advanced discussions with Gilead on potential collaboration
Galapagos announced that, following Gilead entering into a definitive agreement to acquire Ouro Medicines for $1,675m in cash consideration, and up to $500m in contingent milestone payments, Galapagos and Gilead are in advanced partnership discussions. Economically, Galapagos would effectively co-finance Gilead's acquisition and early-stage development of gamgertamig in return for royalties on net sales (20-23%) and freedom to go up to $500m (previously $150m) in the amended OLCA. In our view, t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.